Get started
Author

Eduardo Gabriel Vázquez Saldaña

ORCID: 0000-0001-8194-7199
Observed ORCID: 0000-0001-8194-7199
OpenAlex ID: A5050006558
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
2021 · Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, et al. · The Lancet Infectious Diseases · 182
PDF
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
2023 · Deborah A. Theodore, Angela R. Branche, et al. · JAMA Network Open · 24
PDF
Risk of COVID-19 after natural infection or vaccination
2023 · Anne-Marie Rick, Matthew B. Laurens, et al. · EBioMedicine · 21
PDF
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 8
PDF
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals
2024 · Leigh H. Fisher, Jia Jin Kee, et al. · JAMA Network Open · 7
Works count: 5
Citation count: 242
H-index: 5
I10-index: 3
Year
Topic
Type